KL∗VS heterozygosity reduces brain amyloid in asymptomatic at-risk APOE∗4 carriers
- 23 January 2021
- journal article
- research article
- Published by Elsevier in Neurobiology of Aging
- Vol. 101, 123-129
Abstract
No abstract availableKeywords
Funding Information
- National Institute on Aging
- National Institutes of Health
- Alzheimer's Association
- Medical Research Foundation
This publication has 31 references indexed in Scilit:
- Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer diseaseNeurology, 2014
- Life Extension Factor Klotho Enhances CognitionCell Reports, 2014
- Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracersEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkersThe Lancet Neurology, 2013
- Soluble amyloid precursor protein (APP) regulates transthyretin and Klotho gene expression without rescuing the essential function of APPProceedings of the National Academy of Sciences, 2010
- Alzheimer's Disease Neuroimaging Initiative (ADNI)Neurology, 2010
- The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's diseaseInternational Psychogeriatrics, 2009
- Suppression of Aging in Mice by the Hormone KlothoScience, 2005
- Association of human aging with a functional variant of klothoProceedings of the National Academy of Sciences, 2002
- Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer DiseaseJAMA, 1997